CAMBRIDGE, Mass. & LONDON--(BUSINESS WIRE)--TheraGenetics Limited, a personalized medicine diagnostics company that is developing and commercializing a portfolio of pharmacogenetic diagnostic tests to guide and improve the treatment of central nervous system (CNS) disorders, announced today the appointment of its new Scientific Advisory Board (SAB). The SAB will serve as a strategic asset to the company as it continues to rapidly advance the development of pharmacogenetic tests for critical CNS disorders by identifying biomarkers to determine response and side-effects to drug treatments.
